ArticleClinical, cosmetic and investigational dermatology2025
Methotrexate-Induced Leukocytoclastic Vasculitis: A Case Report and Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case report: Challenging diagnosis of leukocytoclastic vasculitis, caused by recurrent urinary tract infection.SAGE open medical case reports · 2026Article
- Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review.Biologics : targets & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is widely utilized for the management of autoimmune diseases and neoplasms. It may cause several adverse effects, including myelosuppression, hepatitis, and mucositis, and in rare cases, can result in cutaneous vasculitis. We present a case involving a 60-year-old female patient receiving 5 milligrams (mg) of MTX weekly for the treatment of systemic lupus erythematosus (SLE). Her underlying condition was end-stage renal disease (ESRD), requiring hemodialysis (HD). Ten weeks after MTX treatment, she developed oral ulcers, pancytopenia, and hepatitis, followed by multiple non-blanchable erythematous papules, along with a few vesicles and pustules on the neck, trunk and arms. Laboratory results indicated elevated serum MTX levels, and skin biopsy demonstrated dense superficial perivascular and interstitial lymphocytic, eosinophilic, and neutrophilic infiltration, along with nuclear debris and extravasated erythrocytes, indicative of early leukocytoclastic vasculitis (LCV). Direct immunofluorescence (DIF) identified C3 deposits at the dermo-epidermal junction and superficial blood vessels, indicating possible immune complex-mediated vascular disease. The patient was diagnosed with MTX toxicity and histologically confirmed LCV secondary to MTX. MTX toxicity was effectively treated with intravenous folinic acid and cessation of MTX, alongside prescriptions of oral prednisolone and emollients for LCV management. Serum MTX levels became undetectable after a five-day treatment regimen. Skin lesion resolution occurred within one week. Additionally, a review of existing literatures on MTX-induced LCV was conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.